Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Upcoming events – Atara and Aslan await validating results
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Upcoming events – Aveo awaits tivo's death sentence and Glaxo goes long
Aveo will soon find out whether Fotivda has a future, while Glaxo awaits data with an even longer-lasting HIV doublet.
Upcoming events – catalysts approach for Catalyst and Oxurion
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Neon and Neurotrope await signs of proof of concept
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Upcoming events – mid-stage Nash data from NGM and Enanta near
Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.
Go or no go? Karyopharm awaits a verdict on selinexor
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Upcoming events – Pivotal data readouts for Ardelyx and Rhythm will set the tone for next year
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.